Natalie Holles, the chief executive of Audentes Therapeutics, has departed the company as the gene therapy developer's new owner Astellas Pharma fully folds the biotech into its larger organization.
Audentes, which was acquired by Astellas for $3 billion almost a year and a half ago, will now operate under the name Astellas Gene Therapies, the company announced Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,